Age-related function of tumor suppressor gene TP53: Contribution to cancer risk and progression

Experimental Oncology

Volumn 32, Issue 3, 2010, Pages 205-208

  Cherdyntseva, N V ^a   Gervas, P A ^a   Litvyakov, N V ^a   Stakcheeva, M N ^a   Ponomaryeva, A A ^a   Dobrodeev, A Yu ^a   Denisov, E V ^a   Belyavskaya, V A ^b   Choinzonov, E L ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

^b STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

Ageing; Lung cancer; TP53 gene

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; XRCC1 GENE;

ADULT; AGE FACTORS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CODON; DNA-BINDING PROTEINS; EXONS; GENES, P53; GENOTYPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957738564     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-29. (Pubitemid 46744292)
2. Fan R, Wu MT, Miller DP, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomark Prev 2000; 9: 1037-42.
3. Siddique MM, Balram C, Fiszer-Maliszewska L, et al. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev 2005; 14: 2245-52. (Pubitemid 41603274)
4. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Ins 2002; 94: 6851-6902.
5. Schabath MB, Wu X, Wei Q, et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 1581-61.
6. Cherdyntseva NV, Sevostyanova NV, Urazova LN, et al. On genetic and epigenetic risk factors for lung cancer. Mol Med 2005; 3: 49-54 (In Russian).
7. Denisov EV, Cherdyntseva NV, Litvyakov NV, et al. TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet 2009; 192: 93-5.
8. Calle-Martín O, Romero M, Fabregat V, et al. McpI polymorphism of the human p53 gene. Nucleic Acids Res 1990; 18: 4963.
9. Hu Z, Li X, Yuan R, et al. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta- analysis. Breast Cancer Res Treat 2010; 120: 705-14.
10. Offer H, Wolkowicz R, Matas D, et al. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 1999; 450: 197-204. (Pubitemid 29219514)
11. Park JY, Lee SY, Jeon H-S, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 23-7.
12. Hung RJ, Hall J, Brennan P, et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 2005; 162: 925-42. (Pubitemid 41619464)
13. Beauséjour CM, Krtolica A, Galimi F, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-22. (Pubitemid 37021749)
14. Campisi J. Aging, tumor suppression and cancer: high wire-act! Mech Ageing Dev 2005; 126: 51-8.
15. van Heemst D, Mooijaart SP, Beekman M, et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp Gerontol 2005; 40: 11-5. (Pubitemid 40138741)
16. Ørsted DD, Bojesen SE, Tybjærg-Hansen A, et al. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 2007; 204: 1295-301.
17. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual, 2nd edn. New York: Cold Springs Harbor Laboratory 1989; 635 p.
18. Rodier F, Campisi J, Bhaumic D. Two faces of p53: aging and tumor suppression. Nucleic Acid Res 2007; 35: 7475-84.
19. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild type p53 modulated response to chemotherapy in vitro and in vivo. Oncogene 2004; 23: 3328-37. (Pubitemid 38669822)
20. Parrinello S, Coppe J-P, Krtolica A, et al. Stromalepithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 2005; 118: 485-96. (Pubitemid 40310116)
21. Gervas P, Litvyakov N, Stacheeva M, et al. Influence of apoptosis and repair gene polymorphism on neoadjuvant chemotherapy response of malignant tumors. Siberian Oncol J 2009; 34: 41-7 (In Russian).
22. Hun J, Lee G, Jang D. Association of p53 codon 72 polymorphism and NDM2 SNP309 with clinical outcome of advanced non-small cell lung cancer. Cancer 2008; 113: 799-807.
23. Yuan P, Miao X, Zhang X, et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphism. Zhonghua Zhong Liu Za Zhi 2006; 28: 107-10 (In Chinese).